Investing in Life Science Innovation

TVM Capital Life Science is one of the oldest transatlantic Venture Capital funds with teams based in Munich and Montreal.

Learn more

Home
About Us
Team
Senior Advisors
Portfolio
News
Events
Contact

Main Content

Neurimmune and TVM Capital Life Science Announce the Initiation of AL-S Pharma’s Phase 1 Study of AP-101 for the Treatment of ALS

October 18, 2019

Lilly’s REYVOW™ (lasmiditan), The First and Only Medicine in a New Class of Acute Treatment for Migraine, Receives FDA Approval

October 14, 2019

Emovi Announces Results of Clinical Trial to Manage Knee Osteoarthritis with KneeKGTM

October 2, 2019

Footer

About Us

We are creating sustainable value – for patients, the pharmaceutical industry and our investors. Since 1984, TVM Capital Life Science has invested in more than 130 life science companies in Europe, Canada and the United States, currently managing in excess of €900 million from more than 50 investors.

Our Team

TVM Capital Life Science operates with an integrated team from its offices in Montreal and Munich. Our mission is to invest in the development of exciting life science products and the growth of substantial companies in the field that are or aspire to be innovative leaders in their market segment.

Offices

TVM Capital GmbH
Munich, Germany

TVM Life Science Management GmbH
Munich, Germany

TVM Life Science Management Inc.
Montreal, Westmount, Canada

in